| Human papillomavirus is the key causative agent of cervical cancer.HPV preventive vaccines have been widely used around the world,but they cannot treat and eliminate HPV-positive groups.However,the traditional method including radiotherapy,chemotherapy and surgical resection has little effect on patients with advanced or cervical cancer recurrence.The development of new immunotherapy has become a promising way of cervical cancer treatment.T cell epitope peptides are composed of 8-11 amino acids.Specific epitope immunity can accurately target and induce cytotoxic reactions,killing tumor cells.And synthetic peptides have great advantages over intact proteins in terms of safety and mass production.In this study,the T cell epitope polypeptide of HPV16 virus E7 protein is used as antigen to construct peptide epitope vaccines.First,we chemically synthesize HPV16E786-93polypeptide and interact with Cp G adjuvant to form nanoparticles.Subsequently,the size and entrapment rate are determined.It proves that the polypeptide and Cp G can self-assemble into a spherical structure with high stability.Then we cultured DC in vitro and measured the cytokine concentration in the cell culture supernatant after the nanocomposite stimulation.The nanoparticles showed a significant increase.Finally,the anti-tumor effect of the nano-vaccine in mice was observed.The average tumor volume of nanovaccine treated group was only 18%compared with control group.Flow cytometric analysis of the proportion of T cells in the tissues showed that the nanovaccine can significantly stimulate the percentage of T lymphocytes in the tumor,spleen and peripheral blood,indicating that nanovaccine can effectively and stably inhibit TC-1 Transplant the tumor volume of mice and improve the tumor microenvironment.Through the research of this subject,it will provide valuable antigen delivery strategies for future clinical research and lay a theoretical foundation for further exploration of therapeutic HPV vaccines. |
PDF Full Text Request